mTOR pathway is one of the most important and well-studied signalling cascades with respect to cancer. The major controllers of mTOR are the tumour suppressors Hamartin (TSC1) and Tuberin (TSC2), which lies in the heart of this cellular signalling pathway. Mutation in any of these genes will render them unsuccessful to possess tuberin's GTPase activity towards Rheb, a small G-protein, which eventually keeps the mTOR activated. Such mutations lead to tuberous sclerosis complex, a multi-organ disease characterized by non-cancerous tumours in brain, skin, liver, kidney, lungs and heart. Also, it puts an individual at a higher risk of developing cancer in these organs.
